Global rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients.
Centogene is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients.
With headquarters in Rostock, Germany and further operations in Berlin, Germany as well as Cambridge, Massachusetts, USA, Centogene is dedicated to transforming the science of genetic information into solutions and hope for patients with rare diseases and their families. Centogene provides the full spectrum of modern methods and technology for human genetics analysis.
Centogene is active in research and is constantly developing new and innovative products for human genetics. They are focused on helping to end the diagnostic odyssey of their patients by offering the broadest genetic diagnostic portfolio, and on using their global knowledge of rare hereditary diseases to provide solutions for their pharmaceutical partners that accelerate the development of orphan drugs.
Centogene is committed to ‘un-rare’ rare diseases by using their worldwide knowledge in the rare disease market, understanding the epidemiology, analyzing clinical heterogeneity of the more than 3,800 diseases and developing innovative biomarkers. Based on this knowledge Centogene is bringing rationality to treatment decisions and, thereby, accelerating the development of new orphan drugs.
Careventures invested in Centogene together with other leading healthcare and international biotech investors. The capital injected in the company is contributing to accelerate its growth and expansion plans in the business segments of worldwide genetic testing, and pharmaceutical collaborations.